{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:19:20Z","timestamp":1794057560054,"version":"4.8.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Novel monoclonal antibody (mAb)-based therapies targeting CD19 and CD22 (blinatumomab and inotuzumab) have shown high rates of complete remission (CR) and been used as a bridging treatment to potentially curative allogeneic hematopoietic stem cell transplantation (alloHSCT) in adults with relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL). However, limited data exist on the outcome of patients resistant to both mAbs as well as responses to each agent when progressed after the alternate antigen-targeted mAb. Herein, we report outcomes of 29 patients with R\/R B-ALL previously treated with both blinatumomab and inotuzumab. Twenty-five patients (86.2%) received blinatumomab as first mAb (mAb1), and CD19-negative\/dim relapses were observed in 44% of the patients. Inotuzumab induced CR in 68% of the patients for post-blinatumomab relapse regardless of CD19 expression status. The median time between mAb1 and mAb2 was 99 days. Twelve (63.2%) of 19 patients who achieved remission after mAb2 underwent alloHSCT. The median time from mAb2 to alloHSCT was 37.5 days. Acute graft-versus-host disease and nonrelapse mortality were observed in 58.3% (grade 3 or higher, 25%) and 41.7%, respectively. With a median follow-up of 16.8 months after mAb2, 19 patients (65.5%) relapsed, and 21 patients (72.4%) have died. Overall survival was not different between alloHSCT and non-alloHSCT patients. In conclusion, patients with B-ALL who relapsed after blinatumomab could be successfully rescued by inotuzumab as a bridge to alloHSCT but represent an ultra-high-risk group with poor overall survival. Further studies, including novel consolidation and treatment sequence, may improve outcomes of these patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005978","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T22:06:19Z","timestamp":1642543579000},"page":"1432-1443","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab"],"prefix":"10.1182","volume":"6","author":[{"given":"Kitsada","family":"Wudhikarn","sequence":"first","affiliation":[{"name":"Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Division of Hematology and Research Unit in Translational Hematology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-9624","authenticated-orcid":false,"given":"Amber C.","family":"King","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-9117","authenticated-orcid":false,"given":"Mark B.","family":"Geyer","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College of Cornell University, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Roshal","sequence":"additional","affiliation":[{"name":"Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Bernal","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boglarka","family":"Gyurkocza","sequence":"additional","affiliation":[{"name":"Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College of Cornell University, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College of Cornell University, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College of Cornell University, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"issue":"4","key":"2022030216213855900_B1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica."},{"issue":"3","key":"2022030216213855900_B2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood."},{"issue":"11","key":"2022030216213855900_B3","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.bbmt.2019.08.014","article-title":"Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"DeFilipp","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"2022030216213855900_B4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med."},{"issue":"9","key":"2022030216213855900_B5","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1038\/bcj.2016.84","article-title":"Blinatumomab vs historical standard therapy of adult relapsed\/refractory acute lymphoblastic leukemia","volume":"6","author":"G\u00f6kbuget","year":"2016","journal-title":"Blood Cancer J."},{"issue":"36","key":"2022030216213855900_B6","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022030216213855900_B7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/cncr.33340","article-title":"Sequencing of novel agents in relapsed\/refractory B-cell acute lymphoblastic leukemia: blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Badar","year":"2021","journal-title":"Cancer."},{"issue":"8","key":"2022030216213855900_B8","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3324\/haematol.2020.251686","article-title":"Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"106","author":"Geyer","year":"2021","journal-title":"Haematologica."},{"issue":"9","key":"2022030216213855900_B9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am J Hematol."},{"issue":"3","key":"2022030216213855900_B10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cll.2021.03.012","article-title":"Hematopathologic correlates of CAR T-cell therapy","volume":"41","author":"Dolan","year":"2021","journal-title":"Clin Lab Med."},{"issue":"6","key":"2022030216213855900_B11","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"2022030216213855900_B12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"7","key":"2022030216213855900_B13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"2022030216213855900_B14","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1002\/cam4.3731","article-title":"Blinatumomab as first salvage versus second or later salvage in adults with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: results of a pooled analysis","volume":"10","author":"Topp","year":"2021","journal-title":"Cancer Med."},{"issue":"3","key":"2022030216213855900_B15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ajh.24987","article-title":"Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol."},{"issue":"6","key":"2022030216213855900_B16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.25953","article-title":"Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy","volume":"63","author":"Rayes","year":"2016","journal-title":"Pediatr Blood Cancer."},{"key":"2022030216213855900_B17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J."},{"issue":"12","key":"2022030216213855900_B18","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"G\u00f6kbuget","year":"2016","journal-title":"Haematologica."},{"issue":"11","key":"2022030216213855900_B19","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/cncr.23919","article-title":"Outcome of adults with acute lymphocytic leukemia after second salvage therapy","volume":"113","author":"O\u2019Brien","year":"2008","journal-title":"Cancer."},{"issue":"10","key":"2022030216213855900_B20","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/bloodadvances.2019001381","article-title":"Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab","volume":"4","author":"Badar","year":"2020","journal-title":"Blood Adv."},{"issue":"9","key":"2022030216213855900_B21","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.bbmt.2019.04.020","article-title":"Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia","volume":"25","author":"Marks","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022030216213855900_B22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bbmt.2020.01.029","article-title":"Outcomes of allogeneic hematopoietic cell transplantation after salvage therapy with blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"26","author":"Salhotra","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"2022030216213855900_B23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-020-00345-8","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden","volume":"10","author":"DeAngelo","year":"2020","journal-title":"Blood Cancer J."},{"issue":"23","key":"2022030216213855900_B24","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1002\/cncr.32335","article-title":"Transplantation in adults with relapsed\/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer."},{"key":"2022030216213855900_B25","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood-2019-129018","article-title":"Sequential combination of inotuzumab ozogamicin (InO) with low-intensity chemotherapy (mini-hyper-CVD) with or without blinatumomab is highly effective in patients (pts) with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in first relapse","volume":"134","author":"Sasaki","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2022030216213855900_B26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbmt.2012.09.003","article-title":"T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease","volume":"19","author":"Goldberg","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"issue":"10","key":"2022030216213855900_B27","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/j.clml.2020.05.022","article-title":"Blinatumomab or inotuzumab ozogamicin as bridge to allogeneic stem cell transplantation for relapsed or refractory B-lineage acute lymphoblastic leukemia: a retrospective single-center analysis","volume":"20","author":"Stelmach","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"8","key":"2022030216213855900_B28","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"issue":"10299","key":"2022030216213855900_B29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/5\/1432\/1875961\/advancesadv2021005978.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/5\/1432\/1875961\/advancesadv2021005978.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T13:59:08Z","timestamp":1674482348000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/5\/1432\/483549\/Outcomes-of-relapsed-B-cell-acute-lymphoblastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,3,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005978","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]}}}